表纸
市场调查报告书

勃起功能障碍:开发平台分析

Erectile Dysfunction - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 232812
出版日期 内容资讯 英文 109 Pages
订单完成后即时交付
价格
Back to Top
勃起功能障碍:开发平台分析 Erectile Dysfunction - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 109 Pages
简介

所谓勃起功能障碍(ED),是指男性不能维持性交必要的勃起的障碍,也称为阳痿。易罹病素质包含有血缘和体重过剩、伤害、摄取毒品&酒精、药物疗法(抗忧鬱剂、抗组织胺药物、高血压治疗药、止痛药、前列腺癌症治疗药等)等。

本报告提供全球各国的勃起功能障碍(ED)治疗用的开发中产品的开发情形相关分析,产品开发、上市的最新趋势,及临床实验的各阶段的产品一览,主要企业简介,主要药物概要,最新的产业趋势等资讯,为您概述为以下内容。

目录

简介

  • 分析范围

勃起功能障碍(ED)概要

治疗药的开发

  • 勃起功能障碍开发中产品:概要
  • 勃起功能障碍开发中产品:比较分析

各企业开发中的勃起功能障碍治疗药

大学/研究机关研究中的勃起功能障碍治疗药

开发中产品的概要

  • 后期阶段的产品
  • 临床实验阶段的产品
  • 初期阶段的产品
  • 不明确阶段的产品

勃起功能障碍治疗药:开发中的产品一览(各企业)

勃起功能障碍治疗药:研究中的产品一览(各大学/研究机关)

开发勃起功能障碍治疗药的企业

  • Acorda Therapeutics, Inc.
  • Apricus Biosciences, Inc.
  • Biopharm GmbH
  • Corridor Pharmaceuticals Inc.
  • Futura Medical Plc
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Humanetics Corporation
  • IntelGenx Corp.
  • Mezzion Pharma Co. Ltd.
  • 田边三菱制药
  • Monosol Rx, LLC
  • NAL Pharmaceuticals Ltd.
  • Pacific Therapeutics Ltd.
  • Palatin Technologies, Inc.
  • Pharmicell Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Suda Ltd
  • U.S. Stem Cell, Inc.
  • Yungjin Pharm. Co., Ltd.

勃起功能障碍:治疗药的评估

  • 单剂治疗药的情况
  • 并用治疗药的情况
  • 各标的
  • 各作用机制
  • 各投药法
  • 各分子类型

药物简介

  • (PDE-5 抑制剂 + 鹽酸toramadoru)
    • 产品概要
    • 功能机制
    • 研究开发(R&D)的发展情形
  • AdipoCell
  • alprostadil
  • AP-102
  • avanafil
  • BIO-300
  • BL-214
  • cimaglermin alfa
  • fadanafil
  • HCP-1302
  • HCP-1303
  • Immpocellgram
  • MED-2005
  • 硝化甘油
  • 心血管疾病、代谢异常、勃起功能障碍治疗用 G蛋白偶联受体Mas活性肽
  • 椎间盘退化性疾病、骨折、帕金森氏症、勃起功能障碍治疗用合成蛋白质
  • 柠檬酸Sildenafil
  • 血管功能障碍、 PAH、勃起功能障碍治疗用精氨酸抑制剂
  • 勃起功能障碍治疗用 PDE5抑制剂
  • SUD-003
  • 女性的性功能障碍、勃起功能障碍治疗用黑皮质素4受体工作合成肽
  • T-6932
  • tadalafil
  • TF-0092
  • TPN-171
  • TPN-729
  • TR-399
  • udenafil
  • VLFIA-330
  • YBH-1603

勃起功能障碍治疗药:开发中产品的最新趋势

勃起功能障碍治疗药:开发暂停的产品

勃起功能障碍治疗药:开发中止的产品

勃起功能障碍相关产品的开发里程碑

  • 值得注意的最新趋势、新闻稿
  • ■附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11082IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H1 2019, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 5, 7, 10, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Erectile Dysfunction - Overview
  • Erectile Dysfunction - Therapeutics Development
  • Erectile Dysfunction - Therapeutics Assessment
  • Erectile Dysfunction - Companies Involved in Therapeutics Development
  • Erectile Dysfunction - Drug Profiles
  • Erectile Dysfunction - Dormant Projects
  • Erectile Dysfunction - Discontinued Products
  • Erectile Dysfunction - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Erectile Dysfunction, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Erectile Dysfunction - Pipeline by Adamis Pharmaceuticals Corp, H1 2019
  • Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, H1 2019
  • Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H1 2019
  • Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, H1 2019
  • Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Cure Pharmaceutical Inc, H1 2019
  • Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2019
  • Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2019
  • Erectile Dysfunction - Pipeline by Humanetics Corp, H1 2019
  • Erectile Dysfunction - Pipeline by Karessa Pharma Holding AB, H1 2019
  • Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2019
  • Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Suda Pharmaceuticals Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H1 2019
  • Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H1 2019
  • Erectile Dysfunction - Dormant Projects, H1 2019
  • Erectile Dysfunction - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Erectile Dysfunction - Dormant Projects, H1 2019 (Contd..2), H1 2019
  • Erectile Dysfunction - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Erectile Dysfunction, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top